Relevant community:
Primary: PKU, HCU, MSUD, UCDs, and all rare disease communities seeking access to innovative therapies.
Secondary: Healthcare professionals, researchers, policy makers, and anyone interested in how medicines are evaluated, funded, and made available in Canada.
What this means for Amino Allies in Canada
This opinion article explores how recent efforts by the United States to reduce prescription drug prices may expose broader challenges within Canada's own drug evaluation and reimbursement system. While the article discusses international policy, its message is highly relevant to Canadians living with inherited metabolic disorders who often experience lengthy delays before new therapies become publicly available.
The authors argue that Canada's health technology assessment (HTA) process may undervalue innovation and the lived experience of patients by relying heavily on traditional economic models such as quality-adjusted life years (QALYs). They suggest these methods may not fully reflect the realities faced by individuals living with rare diseases or the long-term value of innovative treatments.
CanPKU+ continues to advocate for patient-centred decision-making where lived experience, disease burden, caregiver impact, and quality of life are considered alongside economic evidence. This article contributes to an ongoing national conversation about how Canadians access innovative medicines and how those decisions are made.
Article
Trump's Drug Price Push Exposes Canada's Pricing Flaws
An opinion article examining how Canada's drug assessment and pricing systems may influence access to innovative medicines.
Written by John Adams and Nigel Rawson and published by the Macdonald-Laurier Institute's Inside Policy.
The authors argue that Canada's current health technology assessment process contains several structural weaknesses that can delay or limit patient access to new medicines. They suggest that current assessment methods may underestimate both the value of scientific innovation and the real-world experiences of patients and caregivers.
Among the concerns discussed are Canada's continued reliance on QALY-based cost-effectiveness modelling, the use of list prices rather than negotiated prices during assessments, and economic thresholds that have changed little despite advances in medicine, inflation, and increasing treatment complexity. The article also proposes greater use of real-world evidence after medicines become available to better understand their true value in clinical practice. :contentReference[oaicite:0]{index=0}
For individuals and families affected by rare inherited metabolic disorders, these policy discussions are more than theoretical. Decisions made during Canada's drug review and reimbursement processes directly influence how quickly new therapies become available, who is eligible to receive them, and under what conditions they may be funded.
About the author
One of the article's authors, John Adams, serves as Advocacy Advisor for CanPKU+. John brings decades of experience in public policy, governance, and patient advocacy, and contributes his expertise to help advance equitable access to care and treatment for Canadians living with inherited metabolic disorders.
Continue reading the full article:
CanPKU+ perspective: This article is shared to encourage discussion about medicine access and health policy. The views expressed are those of the authors and are not necessarily official positions of CanPKU+. We believe informed discussion, evidence-based policy, and meaningful patient engagement all play important roles in improving access to innovative therapies for Canadians living with rare diseases.
